| Year |
Citation |
Score |
| 2022 |
Liu D, Qi X, Wei X, Zhao L, Wang X, Li S, Wang Z, Shi L, Xu J, Hong M, Liu Z, Zhao L, Wang X, Zhang B, Zhang Y, et al. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy. Theranostics. 12: 7788-7803. PMID 36451856 DOI: 10.7150/thno.75037 |
0.621 |
|
| 2022 |
Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang JS, Wang F, Liu ZL, Cao YJ. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. PMID 35981465 DOI: 10.1182/blood.2022016243 |
0.516 |
|
| 2021 |
Cao YJ, Yu C, Wu KL, Wang X, Liu D, Tian Z, Zhao L, Qi X, Loredo A, Chung A, Xiao H. Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics. 11: 9107-9117. PMID 34522229 DOI: 10.7150/thno.62444 |
0.402 |
|
| 2021 |
Cao YJ, Wang X, Wang Z, Zhao L, Li S, Zhang Z, Wei X, Yun H, Choi SH, Liu Z, Zhao L, Kazane SA. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. Acs Synthetic Biology. PMID 33856201 DOI: 10.1021/acssynbio.1c00007 |
0.607 |
|
| 2019 |
Zhao L, Cao YJ. Engineered T Cell Therapy for Cancer in the Clinic. Frontiers in Immunology. 10: 2250. PMID 31681259 DOI: 10.3389/Fimmu.2019.02250 |
0.459 |
|
| 2019 |
Zhang Y, Fang C, Wang RE, Wang Y, Guo H, Guo C, Zhao L, Li S, Li X, Schultz PG, Cao YJ, Wang F. A tumor-targeted immune checkpoint blocker. Proceedings of the National Academy of Sciences of the United States of America. PMID 31332018 DOI: 10.1073/Pnas.1905646116 |
0.59 |
|
| Show low-probability matches. |